PAVmed Inc.

What they do

PAVmed operates through subsidiaries, including Lucid Diagnostics (marketing EsoGuard and EsoCheck for esophageal cancer screening), Veris Health (digital health and implantable monitor), and a medical device portfolio (PortIO, Octeris). The company uses a shared services model and finances subsidiaries independently.

Revenue drivers

• Lucid Diagnostics (EsoGuard/EsoCheck) — EsoGuard is a DNA test for esophageal precancer; revenue recognized by Lucid (e.g., $1.5 million in 2Q26, 2,770 tests processed).
• Veris Health — Digital health tools and implantable physiological monitor; commercial engagement with OSU-The James, but revenue not separately disclosed.
• PAVmed corporate and other — Company-level revenue has been minimal; total company revenue was only $33,000 in Q2 2026 and $71,000 for full-year 2025.

Recent performance

For Q2 2026, PAVmed reported revenue of $33,000 and an operating loss of $7.0 million. GAAP net loss attributable to common stockholders was approximately $5.5 million, or $(0.87) per diluted share. Cash and equivalents were $3.8 million at June 30, 2026, up from $1.5 million at year-end 2025. Lucid recognized $1.5 million in EsoGuard revenue and processed 2,770 tests in Q2 2026. The company's equity method investment in Lucid was valued at $33.5 million at June 30, 2026.

Strategy

PAVmed aims to commercialize healthcare technologies through independently financed subsidiaries. It is supporting Lucid's expansion of EsoGuard, pursuing partnerships for Veris' platform, and developing a device portfolio including PortIO and Octeris. The company also continues to evaluate internal development and external licensing opportunities.

Risks

• Going concern and liquidity — Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
• Reliance on capital raises — The company and its subsidiaries have faced significant challenges raising capital under current market conditions.
• Limited revenue and operating losses — PAVmed has incurred operating losses since inception and revenue is minimal, with no assurance of profitability.
• Regulatory and reimbursement uncertainty — EsoGuard relies on FDA enforcement discretion for LDTs, and coverage policies like the first laboratory benefit manager policy are new and uncertain.

Outlook

Management expects Veris to continue toward an early 2027 FDA 510(k) submission for its implantable monitor. PortIO is advancing its FDA pre-submission process with a meeting planned for 4Q26. Octeris is preparing for a clinical validation study at the University of North Carolina. Lucid continues to pursue commercial coverage and payor engagement for EsoGuard.